Visit Saxenda (liraglutide) is one of the injectable options approved by Health Canada for the pharmacological management of weight in adults who meet certain clinical criteria. Unlike the weekly GLP-1 agonists that are becoming increasingly well-known to the public, Saxenda is distinguished by its daily injection—a difference that directly influences the choice of treatment based on each patient’s profile.
On this page
- What is Saxenda (liraglutide)?
- How Does Liraglutide Work?
- Who is eligible for Saxenda?
- Differences Between Saxenda and Weekly GLP-1 Medications
- Protocol for Administration and Medical Monitoring
- Side Effects and Precautions
- Access to Saxenda in Quebec
- Myths and misconceptions
- Frequently asked questions
What is Saxenda (liraglutide)?
Visit liraglutide is the active ingredient in Saxenda, a GLP-1 (glucagon-like peptide-1) receptor agonist—a hormone naturally secreted by the intestine after a meal. Saxenda is approved by Health Canada specifically for chronic weight management in adults, as an adjunct to a reduced-calorie diet and increased physical activity.
Saxenda was one of the first GLP-1 agonists approved for this specific indication, before the introduction of weekly formulations. It remains a viable option for certain patient profiles, particularly those for whom a more gradual dose titration is preferable.
To remember
- Saxenda contains liraglutide, a GLP-1 agonist
- Daily subcutaneous injection, as opposed to weekly formulations
- Approved by Health Canada for weight management in adults
- Always prescribed as a supplement to a diet and exercise plan
- Requires a prior medical evaluation and regular follow-up
- Is not a stand-alone solution without clinical support
How Does Liraglutide Work?
Liraglutide acts on several physiological mechanisms involved in the regulation of appetite and satiety:
Effects on Appetite
- Slower gastric emptying, prolonging the feeling of fullness
- Action on the appetite-regulating centers in the hypothalamus
- Reduced hunger cues between meals
Associated metabolic effects
- Improved insulin sensitivity in some patients
- Positive effect on certain cardiometabolic markers; to be evaluated on an individual basis with the treating physician
Who is eligible for Saxenda?
Eligibility for Saxenda is based on specific clinical criteria, which are evaluated by a doctor:
| Criteria | General Threshold |
|---|---|
| Body Mass Index (BMI) | ≥ 30 kg/m² |
| BMI with associated comorbidities | ≥ 27 kg/m² |
| Preliminary Medical Evaluation | Required |
These thresholds are general guidelines and do not replace an individualized assessment. Certain medical conditions, personal history, or family history may influence the clinical decision in different ways.
Differences Between Saxenda and Weekly GLP-1 Medications
Frequency of administration
- Saxenda : subcutaneous injection daily
- Next-generation GLP-1 agonists: injection weekly
Why this option may be suitable for some patients
- More precise, gradual titration, with the dose adjusted gradually over several weeks
- Faster elimination of the molecule in the event of adverse effects
- A suitable option if a weekly formulation is not well tolerated
The choice between the various options remains an individualized medical decision, never a default choice based on the popularity of a treatment.
Protocol for Administration and Medical Monitoring
Stepwise titration
Treatment generally begins with a low dose, which is gradually increased based on tolerance, under medical supervision. This gradual approach is intended to minimize initial gastrointestinal side effects.
Clinical follow-up required
- Comprehensive initial evaluation (medical history, comorbidities, contraindications)
- Periodic Monitoring of Treatment Response
- Adjustments Based on Tolerance and Clinical Goals
- Reassessment of the appropriateness of continuing treatment in the medium term
Side Effects and Precautions
Like any pharmacological treatment, Saxenda carries potential side effects, most commonly related to digestion (nausea, temporary gastrointestinal effects at the start of treatment). Certain contraindications exist, particularly specific personal or family medical histories. Only a healthcare professional can determine whether this treatment is appropriate based on a patient’s complete medical history.
Access to Saxenda in Quebec
Access to Saxenda requires a medical consultation to assess eligibility, medical history, and health goals. Our service locations in Quebec offer both in-person and telemedicine consultations for this type of assessment.
A comprehensive medical evaluation is the first step in determining whether Saxenda is an appropriate option for you. Make an appointment at one of our service locations in Quebec, or choose a online consultation. Companies interested in a wellness program for their employees can review our offerings for companies.
Myths and misconceptions
«Saxenda replaces diet and exercise»
False. Saxenda is approved as an adjunct to a diet and exercise plan, never as a substitute.
«Daily injections are being phased out in favor of weekly formulations.»
Nuanced. The frequency of administration does not indicate a hierarchy of efficacy—the choice depends on the clinical profile and individual tolerance.
«Anyone can get Saxenda»
False. A medical evaluation and a prescription are required, along with monitoring of clinical eligibility.
«The side effects are automatic and severe.»
Nuanced. Temporary gastrointestinal side effects are common at the start of treatment, but their severity varies greatly from person to person and generally subsides with gradual dose titration.
«The treatment is permanent.»
Nuanced. The duration of treatment is determined in consultation with the treating physician based on the clinical response and the established goals.
Frequently asked questions
Is Saxenda covered by RAMQ?
Coverage varies depending on the insurance plan and eligibility criteria. It is recommended that you check your specific coverage with your insurer or the RAMQ.
How long before I see results?
The timeframes vary from person to person depending on several individual factors. Regular medical follow-up allows for an assessment of progress and adjustments to the treatment plan.
Can Saxenda be combined with other treatments?
Any combination of treatments must be evaluated and approved by a doctor, who will take into account possible interactions and the patient's complete medical history.
Is Saxenda suitable for everyone?
No. Eligibility depends on specific clinical criteria (BMI, comorbidities, medical history) that are evaluated on a case-by-case basis during the medical consultation.
What is the difference between Saxenda and Wegovy?
Both are GLP-1 agonists, but they have different active ingredients (liraglutide vs. semaglutide) and different dosing schedules (daily vs. weekly). The choice depends on an individualized medical evaluation.
Sources
- Health Canada — Pharmaceutical Products Database
- National Institute for Excellence in Health and Social Services (INESSS)
- Quebec Ministry of Health and Social Services (MSSS)
- Quebec College of Physicians (CMQ) — Guidelines on Weight Management
- Quebec Health Insurance Board (RAMQ)
Recommended Reading
- Ozempic generic in Canada: price, access, and indications
- Mounjaro in Quebec: The Complete Guide
- World Obesity Day: Medical Care and Treatments Available in Quebec
- GLP-1 Agonists: A Comparison of Options Approved in Quebec
- Multidisciplinary Support for Weight Management
This information is provided for educational purposes only and is not a substitute for the advice of a healthcare professional. Consult a doctor if you have any questions about your health.
Omicron Clinic
Need to consult a doctor?
In-person or via telemedicine, anywhere in Quebec.
We accept insurance. Telemedicine consultations available 7 days a week. No family doctor required.
